MRL Ventures Fund
Investing in the Future

Investing globally in early-stage therapeutics companies to transform patient care.

About Us

MRL Ventures Fund (MRLV) invests in innovative therapeutics companies that are developing transformative medicines that have the potential to meaningfully improve the lives of patients. MRLV is based in Cambridge, MA and is actively seeking investment opportunities globally.

We are:

Looking for the highest quality, differentiated science that will redefine patient care

Committed to backing imaginative scientists and proven entrepreneurs

Agnostic to therapeutic area or modality


We do not ask for any product or technology rights as a condition of investment. We do not invest in medical devices, diagnostic platforms or digital health. For digital health opportunities, please visit Global Health Innovation Fund (GHI).

BY THE NUMBERS

$250 million fund

> $2.5 BILLION
Total Capital Raised for Portfolio

>$100 million deployed


OUR SCOPE

Therapeutics

Preclinical stage

Any modality

Delivering More than Capital

Investments

Traditional seed and early-stage company investments

Therapeutics companies—from concept to IND. Seek to invest up to $15 million per company, providing long-term, and committed capital

Lead or join a syndicate of investors and play an active role on company boards

Transparent and streamlined investment process

Company Involvement

Over the life of the company, we will continue to provide capital and expertise. We protect the confidentiality of our current and future portfolio companies by providing a robust firewall from the rest of the corporation.

At a portfolio company’s choosing, MRLV can act as a conduit to the larger corporate organization to solicit advice / expertise.

Our Portfolio Companies

Active

Caraway is developing novel small molecules that modulate mitophagy and restore cellular imbalance in neurodegenerative diseases.
Carisma’s platform technology confers antigen-specific recognition to macrophages, creating novel cellular therapeutics (CAR-Macrophages) with initial focus in oncology.
Entrada is treating devastating diseases through the intracellular delivery of biologics.
Hotspot Therapeutics is using computational predictions to identify and modulate novel regulatory allosteric pockets
Imago is a clinical stage company focused on epigenetic therapeutics for oncology and other serious diseases.
Lava is developing proprietary bispecific gamma/delta T-cell engagers for oncology.
LifeMine has developed a genomically-enabled drug discovery engine that leverages fungal biology to identify novel chemical matter that could address previously intractable therapeutic targets.
Tidal is developing a gene therapy approach to engineering and reprogramming the immune system in situ.
Tallac Therapeutics is developing immunomodulating polynucleotides.
Xilio Therapeutics is creating a new class of ultra-potent immunotherapies that are activated selectively within the tumor

Acquired & IPOs

Alector is developing therapies that harness the immune system to treat neurodegenerative disorders and cancer. Alector is a publicly listed company [NASDAQ:ALEC].
Kymera is developing next-generation targeted protein degraders for oncology and inflammation. Kymera is a publicly listed company [NASDAQ: KYMR].
miRagen is a clinical stage company developing innovative therapeutics focused on microRNAs for various diseases. miRagen is a publicly listed company (NASDAQ: MGEN).
Spero is a multi-asset, clinical stage company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero is a publicly listed company (NASDAQ: SPRO).
Translate Bio develops RNA therapeutics using the body’s own machinery to produce proteins to treat diseases caused by the dysregulation of gene expression. Translate is a publicly listed company (NASDAQ: TBIO).
Visterra is a clinical stage company focused on applying its novel Hierotope platform to identify unique epitopes and rationally design and engineer precision biologics for serious diseases. (Acquired by Otsuka)

Our Team

Our team is growing and has years of accumulated experience as scientists, investors, entrepreneurs, and business development & licensing leaders in both biotechnology and pharmaceutical companies. This broad experience enables a rich engagement with portfolio companies and co-investors.

Christine Brennan, Ph.D.
Partner, MRLV

Peter Dudek, Ph.D.
Partner, MRLV

Reza Halse, Ph.D.
President, MRLV

Diana Bernstein, Ph.D.
Senior Associate, MRLV

Olga Danilchanka, Ph.D.
Senior Associate, MRLV

Contact MRL Ventures Fund

MRL Ventures Fund is actively developing a portfolio of early-stage therapeutic companies, which are focused on delivering innovative therapies to improve patient care.

MRL Ventures Fund
320 Bent Street
4th Floor
Cambridge, MA 02141